9 completed. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperphosphatemia: new trials by email Literature Review of Hyperphosphatemia trials Research Report on Hyperphosphatemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis DS-2330b PIB, Placebo, Sevelamer - Hyperphosphatemia | Phase 1 | Completed | Daiichi Sankyo | 40 | 2017-08-17 | 2019-03-25 |
| A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis EOS789, Placebo, Renvela - Hyperphosphatemia | Phase 1 | Completed | Chugai Pharmaceutical | 26 | 2016-12-01 | 2018-09-13 |
| Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan ASP3325 - Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis | Phase 1 | Completed | Astellas Pharma Inc | 24 | 2014-05-12 | 2024-11-05 |
| Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects colestilan, candesartan - Hyperphosphatemia, Chronic Kidney Disease | Phase 1 | Completed | Tanabe Pharma Corporation | 18 | 2013-10-01 | 2026-01-07 |
| Bioequivalence Study of BAY77-1931 Granule Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule, Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet - Hyperphosphatemia | Phase 1 | Completed | Bayer | 59 | 2010-01-01 | 2014-06-23 |
| Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia FOSTRAP Chewing Gum, Placebo chewing gum - Hyperphosphatemia, Chronic Kidney Disease | Phase 1 | Completed | Denver Nephrologists, P.C. | 121 | 2010-01-01 | 2011-01-07 |
| Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers Calcium Acetate Oral Solution 667 mg per 5 mL, Calcium Acetate 667 mg GelCaps, Calcium Citrate 950 mg Caplets - Hyperphosphatemia | Phase 1 | Completed | Fresenius Medical Care North America | 46 | 2008-08-01 | 2009-02-09 |
| The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients Niacinamide, Placebo - Hyperphosphatemia | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 17 | 2006-10-01 | 2007-07-30 |
| The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients Niacinamide - Hyperphosphatemia | Phase 1 | Completed | Washington University School of Medicine | 40 | 2006-04-01 | 2009-01-16 |
Renal Insufficiency, Chronic (3) · Chronic Kidney Disease-Mineral and Bone Disorder (2) · Kidney Failure, Chronic (2)
Metabolic Diseases (9) · Nutritional and Metabolic Diseases (9) · Phosphorus Metabolism Disorders (9) · Chronic Disease (5) · Disease Attributes (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Renal Insufficiency (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Avitaminosis (2)
Niacinamide (2) · Sevelamer (2) · ASP3325 (1) · Calcium Citrate (1) · calcium acetate (1) · candesartan (1) · cholebine (1) · lanthanum carbonate (1)
Washington University School of Medicine (2) · Astellas Pharma Inc (1) · Bayer (1) · Chugai Pharmaceutical (1) · Daiichi Sankyo (1) · Denver Nephrologists, P.C. (1) · Fresenius Medical Care North America (1) · Tanabe Pharma Corporation (1)
United States (6) · Japan (2) · United Kingdom (1)
Antoinette A. Pragalos, MD (1) · Daniel O Young, MD (1) · Daniel W Coyne, M.D> (1) · Geoffrey A Block, MD (1) · Jim Bush, Dr (1)